ResearcherUniversity of Nebraska Medical CenterActive in the last 2 years
Seema C. Parte
Matched on ORCID iD 0000-0002-2879-9534; OpenAlex author ID A5086717421. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 34
2022: 5 papers · 2023: none · 2024: 1 paper
Papers 6
- Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis. Co-author DOI 10.1053/j.gastro.2023.12.018↗
- Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbcan.2021.188669↗
- Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215922↗
- Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
- PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer. Co-author DOI 10.1038/s41419-022-05258-x↗
- A p130Cas-Mediated Mechanism Governs Acinar to Ductal Metaplasia and the Initiation of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1053/j.gastro.2022.01.042↗
Closest collaborators
The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Rama Krishna Nimmakayala · 6 shared papers, 2022–2024 · strength 1.00
- Paper Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma. DOI 10.1016/j.bbcan.2021.188669↗
- Paper A p130Cas-Mediated Mechanism Governs Acinar to Ductal Metaplasia and the Initiation of Pancreatic Ductal Adenocarcinoma. DOI 10.1053/j.gastro.2022.01.042↗
- Paper Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LA… DOI 10.1053/j.gastro.2023.12.018↗
- Surinder K. Batra · 6 shared papers, 2022–2024 · strength 1.00
- Paper Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma. DOI 10.1016/j.bbcan.2021.188669↗
- Paper A p130Cas-Mediated Mechanism Governs Acinar to Ductal Metaplasia and the Initiation of Pancreatic Ductal Adenocarcinoma. DOI 10.1053/j.gastro.2022.01.042↗
- Paper Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LA… DOI 10.1053/j.gastro.2023.12.018↗
- Moorthy Palanimuthu Ponnusamy · 6 shared papers, 2022–2024 · strength 1.00
- Paper Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma. DOI 10.1016/j.bbcan.2021.188669↗
- Paper A p130Cas-Mediated Mechanism Governs Acinar to Ductal Metaplasia and the Initiation of Pancreatic Ductal Adenocarcinoma. DOI 10.1053/j.gastro.2022.01.042↗
- Paper Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LA… DOI 10.1053/j.gastro.2023.12.018↗
- Sanchita Rauth · 4 shared papers, 2022–2024 · strength 0.55
- Paper Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LA… DOI 10.1053/j.gastro.2023.12.018↗
- Paper PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer. DOI 10.1038/s41419-022-05258-x↗
- Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
- Palanisamy Nallasamy · 3 shared papers, 2022–2024 · strength 0.43
- Paper Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LA… DOI 10.1053/j.gastro.2023.12.018↗
- Paper PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer. DOI 10.1038/s41419-022-05258-x↗
- Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
- Jesse L. Cox · 3 shared papers, 2022–2024 · strength 0.43
- Paper Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LA… DOI 10.1053/j.gastro.2023.12.018↗
- Paper PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer. DOI 10.1038/s41419-022-05258-x↗
- Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
- Ayoola O. Ogunleye · 2 shared papers, 2022–2024 · strength 0.31
- Subodh M. Lele · 2 shared papers, 2022–2024 · strength 0.31
- Pranita Atri · 2 shared papers, 2022 · strength 0.23
- Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Lynette M. Smith · 2 shared papers, 2022 · strength 0.23
- Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Parthasarathy Seshacharyulu · 2 shared papers, 2022 · strength 0.23
- Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Ramakanth Chirravuri‐Venkata · 2 shared papers, 2022 · strength 0.23
- Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Ashu Shah · 2 shared papers, 2022 · strength 0.23
- Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Saravanakumar Marimuthu · 2 shared papers, 2022 · strength 0.23
- Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Sushil Kumar K · 2 shared papers, 2022 · strength 0.23
- Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Frank Leon · 1 shared paper, 2024 · strength 0.18
- Shailender Singh · 1 shared paper, 2024 · strength 0.18
- Zahraa Wajih Alsafwani · 1 shared paper, 2024 · strength 0.18
- Venkatesh Varadharaj · 1 shared paper, 2022 · strength 0.14
- Nivedeta Krishna Kumar · 1 shared paper, 2022 · strength 0.14
- Rakesh C. Kukreja · 1 shared paper, 2022 · strength 0.12
- Chunmeng Zhang · 1 shared paper, 2022 · strength 0.12
- Rakesh Bhatia · 1 shared paper, 2022 · strength 0.12
- Sakthivel Muniyan · 1 shared paper, 2022 · strength 0.11
- Sanjib Chaudhary · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.